Anti-MSLN antibody-drug conjugate anetumab ravtansine is composed of a human anti-MSLN IgG1 and a maytansine derivative tubulin inhibitor DM4, which shows selective and potent antitumor activity in xenograft tumor models (57). This evidence concerns the gene MSLN and neoplasm.